ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 355,37
1,00%
Dow Jones
42 992,21
-0,77%
DAX
19 984,32
0,74%
Brent Oil
73,835
0,29%
Bitcoin
93 314,78
-0,22%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Xilio Therapeutics Inc (XLO)

  7. Xilio Therapeutics Inc (XLO) Actualités

XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XLO
DateHeureSourceTitreSymboleSociété
19/12/202413h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
19/12/202413h30GlobeNewswire Inc.Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI NASDAQ:XLOXilio Therapeutics Inc
16/12/202413h30GlobeNewswire Inc.Xilio Therapeutics Appoints Caroline Hensley as Chief Legal OfficerNASDAQ:XLOXilio Therapeutics Inc
03/12/202422h30GlobeNewswire Inc.Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:XLOXilio Therapeutics Inc
07/11/202415h25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
07/11/202415h15GlobeNewswire Inc.Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
07/11/202415h05GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
30/10/202414h01GlobeNewswire Inc.Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
04/10/202415h05GlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
02/10/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
28/09/202403h36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
28/09/202403h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
28/08/202422h01GlobeNewswire Inc.Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:XLOXilio Therapeutics Inc
08/08/202413h30GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
13/06/202422h05GlobeNewswire Inc.Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of DirectorsNASDAQ:XLOXilio Therapeutics Inc
14/05/202413h30GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
07/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XLOXilio Therapeutics Inc
01/04/202422h05GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
28/03/202412h05GlobeNewswire Inc.Xilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingNASDAQ:XLOXilio Therapeutics Inc
28/03/202412h00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
28/02/202422h01GlobeNewswire Inc.Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceNASDAQ:XLOXilio Therapeutics Inc
31/01/202422h01GlobeNewswire Inc.Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:XLOXilio Therapeutics Inc
08/01/202413h30GlobeNewswire Inc.Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesNASDAQ:XLOXilio Therapeutics Inc
07/12/202313h30GlobeNewswire Inc.Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNASDAQ:XLOXilio Therapeutics Inc
09/11/202322h10Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202322h05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202322h01GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
03/11/202317h00GlobeNewswire Inc.Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
31/10/202314h15GlobeNewswire Inc.Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
27/09/202323h02GlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XLO

Dernières Valeurs Consultées

BIT
EBIZ
Global X E-Commerce UCIT...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés